Skip to main content
Aprea Therapeutics, Inc. logo

Aprea Therapeutics, Inc. — Investor Relations & Filings

Ticker · APRE ISIN · US03836J1025 US Professional, scientific and technical activities
Filings indexed 405 across all filing types
Latest filing 2024-03-28 Director's Dealing
Country US United States of America
Listing US APRE

About Aprea Therapeutics, Inc.

https://www.aprea.com/

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes novel cancer therapeutics. The company focuses on precision oncology through a synthetic lethality-based approach, targeting DNA Damage Response (DDR) pathways. Its pipeline consists of small molecule therapeutics designed to exploit vulnerabilities associated with cancer cell mutations, aiming to maximize clinical activity and selectivity while minimizing toxicity. Aprea Therapeutics is conducting clinical trials to evaluate its programs in patients with advanced solid tumors.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2024-03-28 English
8-K
Regulatory Filings
2024-03-26 English
10-K
Annual Report FY 2023
2024-03-26 English
OWNERSHIP DOCUMENT
Director's Dealing
2024-03-15 English
OWNERSHIP DOCUMENT
Director's Dealing
2024-03-15 English
OWNERSHIP DOCUMENT
Director's Dealing
2024-03-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.